The estimated Net Worth of David W Osborne is at least $3.93 Million dollars as of 6 March 2023. David Osborne owns over 690 units of Arcutis Biotherapeutics Inc stock worth over $2,828,344 and over the last 5 years he sold ARQT stock worth over $1,098,362. In addition, he makes $0 as Co-Founder und Chief Technical Officer at Arcutis Biotherapeutics Inc.
Sign up
David Osborne ARQT stock SEC Form 4 insiders trading
David has made over 9 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 690 units of ARQT stock worth $10,529 on 6 March 2023.
The largest trade he's ever made was selling 15,000 units of Arcutis Biotherapeutics Inc stock on 14 December 2020 worth over $450,000. On average, David trades about 3,038 units every 68 days since 2020. As of 6 March 2023 he still owns at least 268,854 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of David Osborne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Osborne biography
Dr. David W. Osborne Ph.D. serves as Co-Founder, Chief Technical Officer of the Company. From April 2008 to May 2016, Dr. Osborne held various positions at Tolmar Inc., including Chief Scientific Officer from December 2013 to May 2016. Prior to joining Tolmar, Dr. Osborne served as Vice President of Product Development at Dow Pharmaceutical Sciences, Inc. from September 2003 to March 2008 and at Atrix Laboratories, Inc. through its acquisition of ViroTex Corp. from 1999 to 2003. He started his career as a formulation group leader at The Upjohn Company and as a Group Leader, Skin Care at Calgon Vestal Laboratories, a subsidiary of Merck & Co., Inc. Dr. Osborne received a B.S. in Chemistry from Missouri State University and a Ph.D. in Physical Chemistry from Missouri University of Science and Technology.
How old is David Osborne?
David Osborne is 59, he's been the Co-Founder und Chief Technical Officer of Arcutis Biotherapeutics Inc since 2017. There are 5 older and 23 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.
What's David Osborne's mailing address?
David's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Insiders trading at Arcutis Biotherapeutics Inc
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron und Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
What does Arcutis Biotherapeutics Inc do?
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
What does Arcutis Biotherapeutics Inc's logo look like?
Complete history of David Osborne stock trades at Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc executives and stock owners
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Watanabe,
President, Chief Executive Officer, Director -
Kenneth Lock,
Chief Commercial Officer -
Todd Franklin Watanabe M.A.,
Pres, CEO & Director -
Patricia Turney,
Senior Vice President - Manufacturing -
Dr. Patrick E. Burnett M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kenneth A. Lock,
Chief Commercial Officer -
Bhaskar Chaudhuri,
Independent Director -
Joseph Turner,
Independent Director -
Ricky Sun,
Independent Director -
Jonathan Silverstein,
Independent Director -
Howard Welgus,
Director -
Halley Gilbert,
Director -
Terrie Curran,
Director -
Patrick Burnett,
Chief Medical Officer -
Keith Klein,
General Counsel -
Frank Pompilio,
Vice President - Medical Affairs -
Lynn Navale,
Vice President - Biometrics -
Charlotte Merritt,
Vice President - Regulatory Affairs -
Ayisha Jeter,
Vice President of Market Access -
Meg Elias,
Vice President - Clinical Operations -
Bethany Dudek,
Vice President - Quality -
David Berk,
Vice President - Clinical Development -
Heather Armstrong,
Vice President of Investor Relations and Corporate Communications -
Kimberly Lathroum,
Vice President of Marketing -
Jay Ramsinghani,
Vice President of Commercial Strategy and Operations -
Scott Burrows,
Vice President - Finance -
John Smither,
Chief Financial Officer -
David Osborne,
Co-Founder, Chief Technical Officer -
Patrick Heron,
Independent Chairman of the Board -
Masaru Matsuda Esq., J.D.,
Gen. Counsel & Corp. Sec. -
Courtney Barton,
Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer -
Eric McIntyre,
Head of Investor Relations -
Dr. David W. Osborne,
Chief Technical Officer -
Patricia A. Turney,
Sr. VP of Operations -
Scott L. Burrows,
CFO & Principal Accounting Officer -
Larry Todd Edwards,
SVP Chief Commercial Officer -
Daniel Estes,
Director -
Neha Krishnamohan,
Director -
David Joseph Topper,
Chief Financial Officer -
Masaru Matsuda,
See Remarks -
Capital Life Sciences Inves...,
-
Advisors Llcorbimed Capital...,
-
Life Sciences Viii, L.P.Fhm...,
-
Matthew Richard Moore,
SVP and Chief Business Officer -
Life Sciences Viii, L.P.Fhm...,
-
Sue Jean Lin,
Director -
Keith R Leonard,
Director -
Life Sciences Viii, L.P.Fhm...,